CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 438,420	$ 239,602
Restricted Cash	31,591
Short-term investments	931,208	597,914
Accounts receivable	33,171	29,428
Unbilled receivable	12,702
Inventories	6,322	10,930
Prepaid expenses and other current assets	63,293	35,623
Total current assets	1,516,707	913,497
Property and equipment, net	90,510	62,568
Land use right, net	12,132	12,465
Intangible assets, net	6,875	7,250
Goodwill	109	109
Deferred tax assets	16,071	7,675
Other non-current assets	11,452	42,915
Total non-current assets	137,149	132,982
Total assets	1,653,856	1,046,479
Current liabilities:
Accounts payable	85,878	69,779
Accrued expenses and other payables	75,037	49,598
Deferred revenue, current portion	15,302	12,233
Tax payable	1,151	9,156
Current portion of long-term bank loan	9,067	9,222
Total current liabilities	186,435	149,988
Non-current liabilities:
Long-term bank loan	51,467	9,222
Shareholder loan	149,217	146,271
Deferred revenue, non-current portion	18,297	24,808
Other long-term liabilities	21,772	31,959
Total non-current liabilities	240,753	212,260
Total liabilities	427,188	362,248
Commitments and contingencies
Equity:
Ordinary shares (par value of US$0.0001 per share; 9,500,000,000 shares authorized; 701,563,184 shares issued and outstanding as of June 30, 2018 (December 31, 2017: 592,072,330 shares))	70	59
Additional paid-in capital	1,804,942	1,000,747
Accumulated other comprehensive income /(loss)	3,114	(480)
Accumulated deficit	(594,929)	(330,517)
Total BeiGene, Ltd. Shareholders' equity	1,213,197	669,809
Noncontrolling interest	13,471	14,422
Total equity	1,226,668	684,231
Total liabilities and equity	$ 1,653,856	$ 1,046,479